SCHEDULE: Viking Global Investors Adjusts BridgeBio Pharma Stake

Viking Global Investors LP and affiliated entities have filed an amendment to their Schedule 13D, reporting a change in beneficial ownership of BridgeBio Pharma, Inc. common stock.

Summary

• This filing is an amendment (Amendment No. 11) to a Schedule 13D, originally filed on July 8, 2019, concerning the common stock of BridgeBio Pharma, Inc.
• The amendment's primary purpose is to remove Mr. David C. Ott as a Reporting Person due to his retirement.
• The reporting persons, including Viking Global Investors LP (VGI) and various affiliated entities and individuals, collectively beneficially own 11,842,434 shares of BridgeBio Pharma's common stock, representing 6.1% of the class.
• This ownership percentage is based on 193,862,871 shares outstanding as of February 12, 2026, as reported in BridgeBio Pharma's Form 10-K filed on February 24, 2026.
• The reporting persons have entered into a joint filing agreement.
• Transactions in the common stock by the reporting persons since February 17, 2026, involved the sale of shares, detailed in Exhibit 99.13.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily concerns administrative changes in reporting beneficial ownership and the removal of a retired individual from the reporting group, rather than indicating new investment activity or strategic shifts.

Risks

• The filing does not explicitly mention any new risks or challenges.
• The primary risk associated with this type of filing is the potential for significant changes in beneficial ownership, which could signal shifts in investor sentiment or strategy.

Future Outlook

The filing does not contain forward-looking statements or guidance from BridgeBio Pharma. It solely pertains to the reporting of beneficial ownership by Viking Global Investors and its affiliates.

Management Comments

• Mr. David C. Ott retired from his roles as Advisory Director of Viking Global Investors LP and Executive Committee Member of affiliated entities, effective March 31, 2026.
• As a result of his retirement, Mr. Ott is no longer a beneficial owner of any shares of BridgeBio Pharma's common stock reported in this filing.

Industry Context

StockSavvy.ai notes that Schedule 13D filings, particularly amendments, are crucial for tracking significant shifts in ownership by institutional investors. This filing indicates a restructuring of reporting responsibilities within Viking Global Investors, rather than a change in their overall investment strategy or stake in BridgeBio Pharma.

Management Changes

Stakeholder Impact

• Shareholders: The filing provides transparency regarding the beneficial ownership of a significant institutional investor, which can influence market perception. The removal of a reporting person due to retirement does not inherently change the overall beneficial ownership percentage.
• Management of BridgeBio Pharma: The filing informs the company's management about the current ownership structure and any changes in reporting entities.
• Regulatory Bodies (SEC): The filing fulfills regulatory disclosure requirements.

Next Steps

• The reporting persons will continue to file amendments to Schedule 13D as required by SEC regulations.
• Further transactions in BridgeBio Pharma's common stock by the reporting persons will be disclosed in subsequent filings.

Key Dates

Keywords

BridgeBio Pharma, Schedule 13D, Viking Global Investors, beneficial ownership, common stock, SEC filing, amendment, securities